Claims
- 1. A method of treating hypertension in a warm-blooded animal comprising administering to said animal on effective amount of a compound, including the individual R and S enantiomers and racemic mixture, represented by the formula: ##STR23## wherein: X is selected from the group consisting of C.sub.1 -C.sub.24 branched or straight chain alkyl;
- C.sub.1 -C.sub.24 branched or straight chain alkoxy; ##STR24## wherein n and m are integers from 0 to 25 and the sum of n and m is less than or equal to 25; substituted phenoxy, wherein the substituents are selected from the group consisting of halogen, trifluoromethyl, phenyl and substituted phenyl; Q is selected from the group consisting of: ##STR25## wherein R.sub.1 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 branched or straight chain alkyl, C.sub.1 -C.sub.4 branched or straight chain alkoxy and C.sub.1 -C.sub.4 branched or straight chain alkylamino; T is a bivalent radical selected from the group consisting of --(CHR).sub.p -- and ##STR26## wherein p is an integer from 1 to 15, the moiety --(CHR).sub.p -- represents an alkylene chain substituted at any position with one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups, and the moiety ##STR27## is bound with the oxygen atom attached directly to the aromatic ring; and Z is
- --N.sup.+ (R.sub.2).sub.3
- wherein R.sub.2 is hydrogen or C.sub.1 -C.sub.4 branched or straight chain alkyl.
- 2. A method of treating hypertension in a warm-blooded animal comprising administering to said animal an effective amount of a compound, including the individual R and S enantiomers and racemic mixture, represented by the formula. ##STR28## wherein X is C.sub.1 -C.sub.24 branched or straight chain alkyl or alkoxy, phenoxy and substituted phenoxy wherein the substituents are selected from C.sub.1 -C.sub.2 0 branched or straight chain alkyl and wherein T is a bivalent radical selected from the group consisting of --(CHR).sub.p -- and ##STR29## wherein p is an integer from 1 to 15, the moiety --(CHR).sub.p -- represents an alkylene chain substituted at any position with one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups, and the moiety ##STR30## is bound with the oxygen atom attached directly to the aromatic ring.
- 3. A method of treating hypertension as defined in claim 2 wherein, in said compound, X is selected from hexadecyloxy, 2-ethyl-4-tetradecylphenoxy, 2-hexyl-4-tetradecylphenoxy, 2-hexyl-5-tetradecylphenoxy, and 2-ethyl-5-tetradecylphenoxy and wherein T is selected from ##STR31##
- 4. A method of treating hypertension as defined in claim 2 wherein said compound comprises 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-1-phenyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-oxide, hydroxide, inner salt.
- 5. A method of treating hypertension as defined in claim 2 wherein said compound comprises 3-(((2-(acetyloxy)-3-(hexadecyloxy)-propoxy)hydroxyphosphinyl)-oxy)-N,N,N-trimethylbenzenemethanaminium, hydroxide, inner salt.
- 6. A method of treating hypertension as defined in claim 2 wherein said compound comprises 7-hydroxy-N,N,N-trimethyl-2-oxo-4((3-tetradecylphenoxy)-methyl)-3,6,8-trioxa-7-phosphaundecan-10-aminium, 7-oxide, hydroxide, inner salt.
- 7. A pharmaceutical composition in dosage unit from comprising a compound, including the individual R and S enatiomers and racemic mixture, represented by the formula: ##STR32## wherein: X is selected from the group consisting of C.sub.1 -C.sub.24 branched or straight chain alkyl;
- C.sub.1 -C.sub.24 branched or straight chain alkoxy; ##STR33## wherein n and m are integers from 0 to 25 and the sum of n and m is less than or equal to 25; substituted phenoxy, wherein the substituents are selected from the group consisting of halogen, trifluoromethyl, phenyl and substituted phenyl; Q is selected from the group consisting of: ##STR34## wherein R.sub.1 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.4 branched or straight chain alkyl, C.sub.1 -C.sub.4 branched or straight chain alkoxy and C.sub.1 -C.sub.4 branched or straight chain alkylamino; T is a bivalent radical selected from the group consisting of --(CHR).sub.p -- and ##STR35## wherein p is an integer from 1 to 15, the moiety --(CHR).sub.p -- represents an alkylene chain substituted at any position with one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups, and the moiety ##STR36## is bound with the oxygen atom attached directly to the aromatic ring; and Z is
- --N.sup.+ (R.sub.2).sub.3
- wherein R.sub.2 is hydrogen or C.sub.1 -C.sub.4 branched or straight chain alkyl in association with a pharmaceutically acceptable carrier.
- 8. A pharmaceutical composition in dosage unit form comprising a compound, including the individual R and S enantiomers and racemic mixture, represented by the formula: ##STR37## wherein X is substituted phenoxy wherein the substituents are selected from C.sub.1 -C.sub.2 0 branched or straight chain alkyl and wherein T is a bivalent radical selected from the group consisting of --(CHR).sub.p -- and ##STR38## wherein p is an integer from 1 to 15, the moiety --(CHR).sub.p -- represents an alkylene chain substituted at any position with one or more C.sub.1 -C.sub.10 alkyl groups or phenyl groups, and the moiety ##STR39## is bound with the oxygen atom attached directly to the aromatic ring, in association with a pharmaceutically acceptable carrier.
- 9. A pharmaceutical composition as defined in claim 8, wherein in said compound X is selected from hexadecyloxy, 2-ethyl-4-tetradecylphenoxy, 2-hexyl-4-tetradecylphenoxy, 2-hexyl-5-tetradecylphenoxy, and 2-ethyl-5-tetradecylphenoxy and wherein T is selected from ##STR40##
- 10. A pharmaceutical composition as defined in claim 8 wherein said compound comprises 7-(acetyloxy)-4-hydroxy-N,N,N-trimethyl-1-phenyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-oxide, hydroxide, inner salt.
- 11. A pharmaceutical composition as defined in claim 8 wherein said compound comprises 3-(((2-(acetyloxy)-3-(hexadecyloxy)-propoxy)hydroxyphosphinyl)-oxy)-N,N,N-trimethyl-benzenemethanaminium, hydroxide, inner salt.
- 12. A pharmaceutical composition as defined in claim 8 wherein said compound comprises 7-hydroxy-N,N,N-trimethyl-2-oxo-4((3-tetradecylphenoxy)-methyl)-3,6,8-trioxa-7-phosphaundecan-10-aminium, 7-oxide, hydroxide, inner salt.--
Parent Case Info
This is a division of application Ser. No. 679,788, filed Dec. 10, 1984, now U.S. Pat. No. 4,762,942.
Divisions (1)
|
Number |
Date |
Country |
Parent |
679788 |
Dec 1984 |
|